Urinary Retention Drugs Market Size, Share & Industry Analysis, By Drug Class (Alpha Blockers, 5 - Alpha Reductase Inhibitors, Others), By Application (Acute Urinary Retention, Chronic Urinary Retention), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) Others and Regional Forecast, 2024-2032

Urinary retention is the inability to empty the urinary bladder completely and is classified among two types i.e. acute and chronic. Acute urinary retention occurs suddenly and last for a short period of time. However, it is a potentially life threatnening condition and requires immediately an emergency treatment. On other hand, chronic urinary retention can persists for a longer period of time. In most cases, patients suffering from chronic condition are able to urinate, but cannot empty their bladder completely. The urinary retention is caused by obstruction in flow of urine due to conditions like urinary tract stones, urethral stricture, prostate cancer, inflammation of urethra, etc. This disorder affects both men and women but, it tends to occur more frequently in men due to aging. According to a study published in Ethopian Journal of Health Science, urinary retention is 10 times more common in male population than in female population worldwide.

Globally, the urinary retention drugs market is being driven by the rising incidence of post-operative urinary retention, increasing prevalence of benign prostatic hyperplasia and availability of drugs for the treatment of the condition in the market. For instamnce, according to the American Academy of Family Physicians, approximately 250,000 surgical procedures are performed for treating patients suffering from benign prostatic hyperplasia each year in U.S. Thus, is expected to fuel the demand of urinary retention drugs for treatment of patients with BPH during the forecast period.

However, presence of alternative treatment options like catheters, urethral dilation and stents are the some of the major factors that may inhibit the growth of global urinary retention drugs market during the forecast period.

Market Segmentation:

By drug class, the global urinary retention drugs market is segmented into alpha blockers, 5-alpha reductase inhibitors and others. In terms of application, the market is categorized into acute urinary retention and chronic urinary retention. Based on distribution channel, the market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.

From a geographical standpoint, the global market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Key Players Covered:

The major companies in the global urinary retention drugs market report includes Sanofi, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc., Eli Lilly and Company and others.

Key Insights

• Epidemiology of Urinary Retention in Key Countries


• Pipeline Analysis, By Key Players


• Key Industry Developments – Partnership, Mergers and Acquisitions

Regional Analysis:

The global urinary retention drugs market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe dominated the global market owing to the increasing prevalence of urinary retention, higher diagnosis rate, and high awareness among patient population towards available treatment options. For instance, according to American Academy of Family Physicians, the annual incidence rate of urinary retention in the U.S is around 4.5 to 6.8 per 1,000 men.

However, increasing patient pool suffering from urinary retention and BPH in Asia Pacific along with increasing awareness among general population towards treatment options for the condition, and increasing diagnosis and treatment rates, is anticipated to fuel the demand of urinary retention drugs market in this region. On other hand, Latin America and Middle East & Africa are projected to register a moderate CAGR during the forecast period.

Segmentation

Urinary Retention Drugs Industry Developments

• In July 2019, Eli Lilly and Company announced acquisition of Loxo Oncology, Inc., a biopharmaceutical company focused on the development and commercialization of selective medicines for patients with genomically defined cancers.